{"id":61115,"date":"2026-03-24T19:02:51","date_gmt":"2026-03-24T11:02:51","guid":{"rendered":"https:\/\/flcube.com\/?p=61115"},"modified":"2026-03-24T19:02:52","modified_gmt":"2026-03-24T11:02:52","slug":"rapport-therapeutics-licenses-rap-219-to-tenacia-bio-328m-deal-targets-greater-china-epilepsy-and-bipolar-markets","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=61115","title":{"rendered":"Rapport Therapeutics Licenses RAP-219 to Tenacia Bio \u2013 $328M Deal Targets Greater China Epilepsy and Bipolar Markets"},"content":{"rendered":"\n

Rapport Therapeutics, Inc.<\/strong> (NASDAQ: RAPP<\/a>) announced a licensing agreement<\/strong> with Tenacia Biopharmaceuticals (Shanghai) Co., Ltd.<\/strong> for RAP-219<\/strong>, a first-in-class TARP\u03b38-specific AMPA receptor negative allosteric modulator<\/strong> in development for focal onset seizures (FOS)<\/strong> and the manic phase of bipolar disorder<\/strong>. The deal grants Tenacia Bio exclusive Greater China rights<\/strong> and provides Rapport with $20 million upfront<\/strong> plus up to $308 million in milestones<\/strong> and tiered royalties up to high teens<\/strong>.<\/p>\n\n\n\n

Transaction Overview<\/h2>\n\n\n\n
Element<\/th>Detail<\/th><\/tr><\/thead>
Licensor<\/strong><\/td>Rapport Therapeutics, Inc. (NASDAQ: RAPP)<\/td><\/tr>
Licensee<\/strong><\/td>Tenacia Biopharmaceuticals (Shanghai) Co., Ltd.<\/td><\/tr>
Asset<\/strong><\/td>RAP-219 (TARP\u03b38-specific AMPA receptor negative allosteric modulator)<\/td><\/tr>
Territory<\/strong><\/td>Greater China<\/strong> (Mainland China, Hong Kong, Macau, Taiwan)<\/td><\/tr>
Indications Licensed<\/strong><\/td>Focal onset seizures (FOS) + manic phase of bipolar disorder<\/td><\/tr>
Deal Value<\/strong><\/td>$20M upfront + up to $308M milestones + high teens royalties<\/strong><\/td><\/tr>
Deal Date<\/strong><\/td>24\u202fMar\u202f2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Product Profile & Mechanism<\/h2>\n\n\n\n
Attribute<\/th>RAP-219 Specification<\/th><\/tr><\/thead>
Mechanism<\/strong><\/td>TARP\u03b38-specific AMPA receptor negative allosteric modulator (NAM)<\/strong><\/td><\/tr>
Target<\/strong><\/td>TARP\u03b38 (transmembrane AMPAR regulatory protein gamma-8) \u2013 brain-specific subunit enabling CNS-selectivity<\/td><\/tr>
Differentiation<\/strong><\/td>First-in-class<\/strong> TARP\u03b38-specific approach; avoids peripheral AMPA receptor effects<\/td><\/tr>
Development Stage<\/strong><\/td>Early clinical studies demonstrating favorable efficacy and tolerability<\/strong><\/td><\/tr>
Global Indications<\/strong><\/td>Focal onset seizures, primary generalized tonic-clonic seizures, manic phase of bipolar disorder<\/td><\/tr>
Greater China Focus<\/strong><\/td>FOS + bipolar mania (Tenacia exclusive); Rapport retains other indications globally<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Rationale<\/h2>\n\n\n\n
Rapport Perspective<\/th>Tenacia Bio Perspective<\/th><\/tr><\/thead>
Non-dilutive capital<\/strong> \u2013 $20M upfront funds U.S.\/EU development<\/td>Exclusive Greater China rights<\/strong> to novel CNS mechanism in high-burden therapeutic areas<\/td><\/tr>
Risk mitigation<\/strong> \u2013 partner bears China development\/commercialization costs<\/td>Local expertise<\/strong> \u2013 neurology\/psychiatry market access and KOL relationships<\/td><\/tr>
Royalty upside<\/strong> \u2013 high teens royalties on China sales without operational investment<\/td>Pipeline diversification<\/strong> \u2013 adds first-in-class asset to Tenacia CNS portfolio<\/td><\/tr>
Validation<\/strong> \u2013 partnership validates TARP\u03b38 platform credibility<\/td>Regulatory advantage<\/strong> \u2013 domestic developer status for NMPA priority review<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Market Context & Commercial Outlook<\/h2>\n\n\n\n
Factor<\/th>Implication<\/th><\/tr><\/thead>
China Epilepsy Market<\/strong><\/td>~9 million patients<\/strong>; RMB 15+ billion annually<\/strong>; high unmet need for focal seizure control with improved tolerability<\/td><\/tr>
Bipolar Disorder in China<\/strong><\/td>~8 million diagnosed<\/strong>; limited approved therapies for acute mania; significant hospitalization burden<\/td><\/tr>
TARP\u03b38 Mechanism Advantage<\/strong><\/td>CNS-selective modulation may offer cognitive-sparing profile<\/strong> vs. non-selective AMPA modulators; addresses unmet tolerability need<\/td><\/tr>
First-in-Class Premium<\/strong><\/td>Novel mechanism supports premium pricing<\/strong> and formulary preference<\/strong> in China innovative drug catalog<\/td><\/tr>
Revenue Potential<\/strong><\/td>Peak China sales RMB 800 million\u20131.2 billion<\/strong> (FOS + bipolar); Tenacia break-even on milestones by 2032<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n